Drug class profile · refreshed daily from federal data

beta2-Adrenergic Agonist

5 molecules in this class, $48.7M combined CY2024 Part D spend across 490K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Oct 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the beta2-Adrenergic Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 5tracked in Part D
CY24 Part D spend: $48.7Mcombined across class
Total Rx claims: 490K206K unique beneficiaries
Generic mfrs (active): 33across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Levalbuterol

Brand: Levalbuterol · 437K Part D claims (CY24) · 191K beneficiaries · First FDA approval: 2009-08-28

7 generic mfrs 516 plans require PA

Low NADAC$0.248

→

Avg plan cost$0.554

Part D spend $29.7M 2× spread, current vs floor

Class share

61%

of class CY24 spend

View profile →

Formoterol Fumarate

Brand: FORMOTEROL FUMARATE · 21K Part D claims (CY24) · 6K beneficiaries · First FDA approval: 2007-10-01

10 generic mfrs 5 plans require PA

Low NADAC$1.27

→

Avg plan cost$3.06

Part D spend $10.5M 2× spread, current vs floor

Class share

22%

of class CY24 spend

View profile →

Arformoterol

32K Part D claims (CY24) · 9K beneficiaries · First FDA approval: 2021-06-22

16 generic mfrs 137 plans require PA

Low NADAC$0.615

→

Avg plan cost$0.627

Part D spend $8.4M 1× spread, current vs floor

Class share

17%

of class CY24 spend

View profile →

Formoterol

— Part D claims (CY24) · First FDA approval: 2021-06-22

Brand-only (no generics) 97 plans require PA

Low NADAC$1.27

→

Avg plan cost$1.31

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Levalbuterol Inhalation

Brand: levalbuterol inhalation · — Part D claims (CY24) · First FDA approval: 2014-09-16

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.